Helen H. Sun
GlaxoSmithKline (United States)(US)University of California, Berkeley(US)
Publications by Year
Research Areas
interferon and immune responses, Cell death mechanisms and regulation, Immune Response and Inflammation, Immune cells in cancer, NF-κB Signaling Pathways
Most-Cited Works
- → Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases(2017)466 cited
- → Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis(2013)135 cited
- → The Identification and Pharmacological Characterization of 6-( tert -Butylsulfonyl)- N -(5-fluoro-1 H -indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase(2016)122 cited
- → Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer(2019)82 cited
- → Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase(2019)68 cited
- → Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases(2019)65 cited
- → Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel(2018)35 cited
- → Functional Mapping of Bas2(2002)11 cited
- → Identification of an antibody‐based immunoassay for measuring direct target binding of RIPK1 inhibitors in cells and tissues(2017)9 cited
- → Biosynthesis of isonitrile lipopeptides(2024)6 cited